Global Eculizumab Market Research Report 2020 by Manufacturers, Regions, Types and Applications By Innovation Market Research, Inc

 Pulichser: XYZResearch

March 2020

 Pages: 109

 IMR 1164

In this report, In the last several years, Global market of Eculizumab developed rapidly, with an average growth rate of 34%. In 2016, Global Revenue of Eculizumab was nearly 2850 M USD; the actual production was about 460 thousand units.The classification of Eculizumab includes Plasma Exchange and Plasma Infusion, and the proportion of Plasma Exchange in 2016 was about 72%, and the proportion was in increasing trend from 2012 to 2016.

Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.

Eculizumab is widely used for patients of PNH, aHUS and others. The most proportion of Eculizumab was used for patients of aHUS, and the proportion in 2016 was about 55%. North America was the largest consumption place, with a consumption market share nearly 40.3% in 2016. Following North America, Europe was the second largest consumption place with the consumption market share of 32.6%.

Alexion is the major player in global Eculizumab market. Soliris (eculizumab) is the first and only therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a lifethreatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.

Geographically, global Eculizumab market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

On the basis of product, we research the production, revenue, price, market share and growth rate, primarily split into
Plasma Exchange
Plasma Infusion

For the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Eculizumab for each application, including

Production, consumption, revenue, market share and growth rate are the key targets for Eculizumab from 2014 to 2026 (forecast) in these regions
Southeast Asia
South America

If you have any special requirements, please let us know and we will offer you the report as you want.

Please fill in the form below to Request for Customized Report
Your personal details are safe and secured with us. Privacy Policy

To request sample copy of this report, please complete the form below verified and secure

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Your personal details are safe and secured with us. Privacy Policy

    What Information does this report contain?

Purchase Options

Offers & Discounts

  • Chapter purchase
  • Historical market data
  • Country level data breakdown
  • Free customization*
  • Discounts for first time
  • Special pricing for
              non-business entities


  • We offer 20% free customization on every purchase.

Get in touch!

  +91 810 895 3541